Hepatocyte Growth Factor Pipeline Report, H2 2020 Edition – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Hepatocyte Growth Factor – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Hepatocyte Growth Factor – Pipeline Review, H2 2020’; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules.
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.
The report ‘Hepatocyte Growth Factor – Pipeline Review, H2 2020’ outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 5, 3, 4 and 3 respectively.
Scope
- The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
- The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics
Key Topics Covered:
Introduction
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Overview
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Companies Involved in Therapeutics Development
- AnGes Inc
- Athira Pharma Inc
- Beijing SH Bio-Tech Corp
- Helixmith Co Ltd
- i2 Pharmaceuticals Inc
- Kringle Pharma Inc
- Minerva Biotechnologies Corp
- Molecular Partners AG
- Yichang Humanwell Pharmaceutical Co Ltd
- Yooyoung Pharm Co Ltd
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Drug Profiles
Ad-HGF – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
ATH-1017 – Drug Profile
beperminogene perplasmid – Drug Profile
donaperminogene seltoplasmid – Drug Profile
Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain – Drug Profile
Gene Therapy to activate HGF for Lung Injury – Drug Profile
Gene Therapy to Activate HGF for Neuro Muscular Disorders – Drug Profile
Gene Therapy to activate HGF for Peripheral Artery Occlusive Disease – Drug Profile
KP-100IT – Drug Profile
Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer – Drug Profile
MP-0250 – Drug Profile
NK-4 – Drug Profile
SL-186 – Drug Profile
SL-188 – Drug Profile
YYB-101 – Drug Profile
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Dormant Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Discontinued Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Product Development Milestones
Featured News & Press Releases
- Oct 21, 2020: Athira Pharma to host educational webinar on the predictive nature of P300 to determine clinical benefit of Alzheimer’s Disease treatments
- Oct 01, 2020: Athira Pharma announces initiation of patient dosing for the LIFT-AD study, a Phase 2/3 clinical trial to evaluate ATH-1017 for treatment of mild-to-moderate Alzheimer’s Disease
- Jul 27, 2020: Helixmith: VM202 CMT Phase I/IIA Trial Launched
- Feb 18, 2020: Helixmith provides update of gene therapy Phase 3 Trial for Painful Diabetic Peripheral Neuropathy
- Feb 04, 2020: AnGes, Inc. initiated Phase 2b study in the U.S. in patients with lower limb ischemic ulcers
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/3hn4z4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
